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Abstract: Lamotrigine has emerged with a distinct place in the pharmacological treatment of 
bipolar disorder, with the potential to treat and prevent bipolar depression, which is the dominant 
and arguably most disabling and under-treated phase of the illness. This review examines the 
published clinical trials of lamotrigine in bipolar treatment. While the data supports its toler-
ability and safety, the strongest evidence for its efﬁ cacy lies in the prevention of bipolar depres-
sion, with weaker evidence for the treatment of acute bipolar depression, refractory unipolar 
and bipolar depression, and rapid cycling bipolar disorder. The total number of published well 
designed trials is small, even the maintenance evidence is derived from two studies. However, 
this relative inadequacy compares favorably with the alternative treatment options for bipolar 
depression, which are marked by poor efﬁ cacy or risk of polarity switch. The designation of 
lamotrigine as ﬁ rst-line treatment for bipolar depression prophylaxis should be done in cogni-
zance of this context, and it would seem prudent to await greater evidence of efﬁ cacy before 
designating lamotrigine as ﬁ rst-line treatment for other bipolar indications. Further randomized 
controlled trials are required to consolidate the available ﬁ ndings and to explore the boundaries 
of lamotrigine’s efﬁ cacy, which may encompass the soft spectral disorders.
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Introduction
Bipolar disorder has been estimated to have a population lifetime prevalence of be-
tween 0.3%–1.5% (Weissman et al 1996), but this ﬁ gure based on DSM-III criteria 
may belie the extent of the full spectrum. The highly recurrent course of bipolar 
disorder (Angst and Sellaro 2000), its poor functional outcomes (Mitchell et al 2004) 
and over-representation in the completed suicide population (Rihmer and Kiss 2002) 
have been well-documented in the literature. In particular, more recent understanding 
of the natural course of bipolar disorder has highlighted its disease burden and chal-
lenged its historical conceptualization as an episodic illness with full inter-episode 
recovery (Kraepelin 2002). Judd and colleagues (Judd et al 2002) have demonstrated 
that over the course of 12.8 years, their cohort of 146 patients with bipolar I disorder 
were symptomatic 47.3% of the time. Signiﬁ cantly, depressive symptoms (present 
over 31.9% of the total follow-up period) predominated over symptoms of any other 
phases. Frequent changes in symptom levels and polarity, and the predominance 
of subsyndromal and minor symptoms were also demonstrated. Paykel et al (2006) 
reported comparable trends in 204 patients with bipolar I disorder, studied over 18 
months. In bipolar II disorder, symptomatic illness has been estimated to be present 
over 53.9% of the 13.4-year follow-up, with depression evident for 50.3% of total 
follow-up time, during which subsyndromal and minor symptoms dominated over 
major depression (Judd et al 2003). These ﬁ ndings indicate a need for treatments 
directed towards the alleviation and prevention of depression, and milder albeit still 
disabling subthreshold depressive symptoms in bipolar disorder.
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The pharmacological management of bipolar disorder 
is rising in complexity, with the continual reﬁ ning of the 
illness spectrum and an expanding pharmacopeia of medi-
cation options that, in monotherapy or in combination, may 
provide more sophisticated means of targeting phasic symp-
toms, polarity changes, and subclinical or minor symptoms. 
Lithium undoubtedly retains the broadest evidence base, 
with substantiated efﬁ cacy in treating manic and depressive 
phases, prophylaxis (Tondo et al 1998; Maj 2003) and the 
reduction of suicide risk (Baldessarini et al 2003). However, 
its side effect proﬁ le and lesser efﬁ cacy in certain subgroups 
(Calabrese and Woyshville 1995) have led to investigations 
of second generation anticonvulsants and atypical antipsy-
chotics as alternative treatments. Valproate and carbamaze-
pine are options in the treatment of mania, mixed states and 
those with rapid cycling illness and comorbid substance 
abuse (Greil 1998; Bowden and Singh 2005), but lack full 
support in prophylaxis and the treatment of bipolar depres-
sion. Atypical antipsychotics, such as risperidone, olanzap-
ine, quetiapine and aripiprazole, all have some evidence of 
efﬁ cacy in the treatment of mania (Segal et al 1998; Berk 
et al 1999; Keck et al 2003; Ketter 2004), but they may ﬁ nd 
a further strength in the growing body of evidence for their 
use in bipolar depression (Tohen et al 2003; Calabrese et al 
2005). Newer anticonvulsants, including gabapentin, topira-
mate and levetiracetam, have had limited investigation that 
have not yielded promising ﬁ ndings in relation to bipolar 
disorder management (Bowden and Karren 2006).
It remains that few medications have an adequate 
evidence base for the treatment and prevention of bipolar 
depression, despite its phenotypic dominance in bipolar 
disorder. The use of antidepressants remains controversial, 
in view of concerns for the risk of antidepressant-induced 
mania and cycle acceleration (Goldberg and Truman 2003). 
In this regard, lamotrigine, with its apparent efﬁ cacy in the 
treatment and prevention of bipolar depression, may have 
a unique place in the bipolar pharmacological armamen-
tarium. Ketter (Ketter and Calabrese 2002) has classiﬁ ed 
maintenance therapies into those that stabilize mood from 
above (mania or hypomania) and those that do so from below 
(depression), with lamotrigine the sole member of the latter 
category. This paper aims to review the evidence for the 
efﬁ cacy of lamotrigine in bipolar disorder, and to provide 
some practical recommendations in the clinical setting.
Methods
A literature search for publications up until August 2006 
was performed, based on the MEDLINE database and 
supplemented by identifying relevant references from 
individual articles. Key search terms used included 
lamotrigine, bipolar disorder, bipolar depression, mania, 
mixed state, major depression, maintenance, pharmacology, 
pharmacokinetics, pharmacodynamics, and clinical trial. 
Original research and review articles were studied.
The pharmacology of lamotrigine
Anticonvulsants are not equivalent to mood stabilizers, 
although several drugs straddle both categories, a fact that 
may have generated often-unfulﬁ lled expectations of effec-
tiveness of anticonvulsants when applied to bipolar disorder. 
The established cross-efﬁ cacy of agents such as valproate, 
carbamazepine and lamotrigine has nevertheless contributed 
to the still imprecise understanding of the pathophysiology 
of bipolar disorder and the development of its treatments, 
although the lack of class effects within the anticonvulsants is 
noteworthy, and complicates extrapolation of mechanism of 
action to pathophysiology. Some agents, such as topiramate, 
do not show efﬁ cacy in the disorder, while others, such as 
valproate, show preferential efﬁ cacy in the manic phase.
Lamotrigine, a phenyltriazine derivative, has been 
demonstrated to possess multiple mechanisms of action, a 
summary of which has been detailed elsewhere (Ketter et al 
2003; Hahn et al 2004). Brieﬂ y, these include the selective 
blockade of the N- and P-type calcium channels in focal 
brain regions, and the voltage-dependent blockade of sodium 
channels via its action on the slow inactivation state that 
occurs when sodium channels are over-activated. Lamotrig-
ine has also been shown to inhibit the release of excitatory 
amino acids such as glutamate and aspartate, and may have 
some agonistic effects on γ-aminobutyric acid (GABA) 
(Ketter et al 2003; Hahn et al 2004). It selectively suppresses 
supranormal neuronal activities without affecting the basal 
neurophysiological state, which has clear implications in 
neuronal stabilization in seizure disorders, but may also be 
a plausible explanation of its action in bipolar disorder, even 
though the pathophysiology of this condition is less clear 
(Hahn et al 2004). Lamotrigine is also believed to act on 
serotonin reuptake, which may contribute to its antidepres-
sant effects (Hahn et al 2004; Bourin et al 2005). There is 
evidence of perhipheral glutamate dysregulation in bipolar 
disorder (Berk et al 2000), and the glutamatergic activity of 
lamotrigine may also be implicated in its therapeutic and 
neuroprotective effects.
The absorption of lamotrigine after oral administration is 
rapid, complete and unaffected by food ingestion. It under-
goes minimal ﬁ rst-pass metabolism, and has a bioavailability 
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of 98% (Peck 1991; Keck and McElroy 2002; Hahn et al 
2004). Peak plasma concentrations are reached in 1.4 to 4.8 
hours, and plasma protein binding is approximately 55%, 
which makes interaction with high plasma protein-binding 
drugs unlikely (Keck and McElroy 2002; Hahn et al 2004). 
Lamotrigine primarily undergoes hepatic metabolization 
through glucuronidation, producing inactive metabolites that 
mainly consist of lamotrigine 2N-glucuronide, and to a lesser 
extent the 5N-glucuronide, N-oxide and N-methyl metabolites, 
all of which are renally excreted (Sinz and Remmel 1991; 
Hachad et al 2002). The kinetics of lamotrigine is linear within 
the daily dose range of 100 to 700 mg. Its mean elimination 
half-life is approximately one day in healthy volunteers (Peck 
1991). Clearance is substantially decreased in the presence of 
hepatic or renal impairment, although age, gender and smoking 
do not appear to have signiﬁ cant impact on kinetics. Clearance 
is also estimated to be about 25% lower in non-Caucasians 
(Keck and McElroy 2002; Hahn et al 2004).
Drug interactions are generally less pronounced with 
newer anticonvulsants compared with older ones, but signiﬁ -
cant interactions may occur between lamotrigine and other 
drugs, primarily via interference with the UDP-glucuronos-
yltransferase enzymes (UGT), which are responsible for the 
hepatic microsomal glucuronidation of lamotrigine and other 
drugs. Interactions can occur when enzyme-inducing drugs 
such as phenytoin, carbamazepine, oxcarbazepine, pheno-
barbital and primidone are co-administered with lamotrigine, 
which may increase its clearance (Hachad et al 2002; Perucca 
2006). Conversely, valproate is an inhibitor of UGT and may 
produce a two-fold increase in lamotrigine serum concentra-
tions (Hachad et al 2002). Dose adjustments are required in 
both of these situations. Potential reduction of lamotrigine 
levels with rifampicin (Ebert et al 2000) and oral contracep-
tives (Sabers et al 2001), and risk of toxicity with sertraline 
(Kaufman and Gerner 1998), have also been documented. 
There has also been evidence for a modest reduction in oral 
contraceptive hormone levels due to lamotrigine, although 
the impact on contraceptive efﬁ cacy may not be affected 
(Sidhu et al 2006). Nevertheless, women on concurrent oral 
contraceptive pills and lamotrigine may beneﬁ t from caution-
ary advice on contraceptive dose adjustments or alternative 
contraceptive methods (Perucca 2006).
Studies of lamotrigine in bipolar 
disorder
Building on anecdotal reports of lamotrigine’s psychotropic 
properties in epileptic and bipolar patients, Calabrese et al 
(Calabrese, Bowden, McElroy, et al 1999) conducted the 
ﬁ rst study to investigate its spectrum of therapeutic activity 
in bipolar disorder. This 48-week, open-label, prospective 
trial used lamotrigine as monotherapy or adjunctive phar-
macotherapy in 75 patients with refractory bipolar I or II 
disorder, who variously presented in depressed, hypomanic, 
manic or mixed phases of the illness. Their results suggested 
that lamotrigine was effective as both monotherapy and 
adjunctive therapy, and for all phases of the illness with 
large magnitudes of improvements. Speciﬁ cally, in the 40 
subjects presenting with depression, 48% showed “marked 
improvement”, deﬁ ned as a 50% or greater reduction in 
the 17-item Hamilton Depression Scale (HAMD); 20% 
showed “moderate improvement”, deﬁ ned as a 26%–49% 
reduction in HAMD; and a mean HAMD reduction of 42%. 
For the 31 subjects presenting with hypomania, mania or 
mixed state, 81% showed “marked improvement” and 3% 
“moderate improvement”, as correspondingly deﬁ ned using 
the mania rating scale (MRS), and a mean score reduction 
of 74% was achieved. These results must be interpreted 
with caution, given the many methodological limitations of 
this preliminary study, such as its treatment-refractory and 
heterogeneous population with regards to both bipolar type 
and phase, open-label non-randomized design, and lack of 
control for concurrent psychotropic use. Furthermore, the 
drop-out rate was high (51%), and largely reﬂ ected adverse 
events and ineffectiveness which jointly accounted for two-
thirds of this ﬁ gure.
Findings of such broad spectrum activity and therapeutic 
magnitude have more recently been reported by a retro-
spective chart review of 587 bipolar disorder outpatients, 
comprising all subtypes and in various illness phases, in a 
private practice setting (Ginsberg 2006). Despite obvious 
methodological limitations, this study had the beneﬁ t of a 
large sample size. Using the Clinical Global Impression-
Improvement (CGI-I) scale as outcome measure, 59.5% 
of patients were rated as either “very much improved” or 
“much improved” on lamotrigine, and a further 20.4% were 
deemed to have “minimally improved”. Response rates were 
comparable across bipolar disorder subtypes (ie, bipolar 
I, II and not otherwise speciﬁ ed) and index mood episode 
(ie, depressed, manic and mixed) for the bipolar I subset. The 
median time from lamotrigine initiation to observed response 
was 95 days, with a mean of 205 days.
There have been a number of published studies of higher-
order design for lamotrigine in bipolar disorder. These have 
speciﬁ cally examined the effects of lamotrigine on mania, 
bipolar depression, rapid cycling illness and bipolar disorder 
maintenance. These are sequentially discussed below.
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Studies in acute mania
In the ﬁ rst double-blind, randomized controlled trial of 
lamotrigine in mania, Ichim and colleagues (Ichim et al 2000) 
allocated 30 hospital inpatients meeting the DSM-IV criteria 
for bipolar I disorder, manic phase, to treatment with either 
lamotrigine or lithium over 4 weeks. Other psychotropic 
agents were discontinued for at least a day prior to com-
mencing the trial. Both treatment arms produced comparable 
response rates and extent of improvement, as measured by 
the MRS, brief psychiatric rating scale (BPRS), CGI sever-
ity (CGI-S) and improvement (CGI-I) scales, and the Global 
assessment of functioning (GAF) scale. Additionally, there 
were no signiﬁ cant differences between the treatment arms 
over the course of the study period, notable given the slow 
dose titration for lamotrigine. This study had several limi-
tations, the strongest of which being its insufﬁ cient power 
arising from the small sample size. The use of a relatively 
low dose of lamotrigine (100 mg/day) and a ﬁ xed lithium 
dose (800 mg/day) may also have confounded the results. 
Such encouraging ﬁ ndings have not been replicated by other 
double-blind trials, although these have been few in number 
and their comparability compromised by differing method-
ologies that were likewise imperfect.
Three such studies were described in a review by Yatham 
(2004). One was an 8-week study of 16 lithium-refractory manic 
and hypomanic patients, which found lamotrigine to be no more 
useful than placebo. Conclusions of efﬁ cacy are difﬁ cult to make 
considering the small sample size and refractory population. 
In the other two cited studies, neither found lamotrigine to be 
superior to placebo in the treatment of acute mania. In the 
3-week monotherapy study, lamotrigine at 50 mg/day (N = 84) 
was compared against lithium, given to reach serum levels of 
0.8 to 1.3 (N = 36), and placebo (N = 95). The second study 
compared lamotrigine at 200 mg/day (N = 74) with lithium 
(N = 78) and placebo (N = 77) as adjunctive therapy to anti-
psychotics over 6 weeks. The low lamotrigine dose used in 
the ﬁ rst study, and the adjunctive design of the second, are 
confounding factors that preclude direct comparisons.
Studies in acute bipolar depression
Monotherapy trials
Several studies have investigated the efﬁ cacy of lamotrigine 
monotherapy with ﬁ ndings relevant to bipolar depression 
(Table 1). Calabrese and colleagues (Calabrese, Bowden, 
Sachs, et al 1999) reported the ﬁ rst double-blind placebo-
controlled trial of lamotrigine monotherapy in the treatment 
of bipolar I depression. They recruited 195 subjects meeting 
the DSM-IV diagnostic criteria for bipolar I disorder who 
were in a major depressive episode. These patients were 
randomized into 3 monotherapy treatment arms of equal size 
(N = 66), consisting of 50 mg/day lamotrigine, 200 mg/day 
lamotrigine and placebo, given over 7 weeks. All psychoactive 
agents except sedatives had been ceased prior to randomiza-
tion, at durations equivalent to 5 half-lives of the drugs. Both 
lamotrigine groups showed moderately larger margins of im-
provement than placebo as measured by HAMD, montgomery-
åsberg depression rating scale (MADRS), CGI-S and CGI-I, 
although only differences on MADRS, CGI-S and CGI-I for 
the lamotrigine 200 mg/day group reached statistical signiﬁ -
cance at the p < 0.05 level. The 200 mg/day group showed 
an earlier response compared with the 50 mg/day group, 
with signiﬁ cant differentiation of the trajectories between the 
Table 1 Randomized, controlled trials of lamotrigine monotherapy in acute bipolar depression
Trial Study arms N Sample Trial length Response rate in percentagea
     in weeks
Calabrese,   Bipolar I  7 HAMD MADRS CGI-I
Bowden, Sachs LTG  66 major   45 48b 41
et al 1999 50 mg/day  depressive     
  LTG  66 episode,   51 54b 51b
  200 mg/day  outpatients    
  Placebo 66   37 29 26
        
Brown EB   Bipolar I 7 MADRS  CGI-S
et al 2006 LTG 205 major   59.7  64.4
  OFC 205 depressive episode  68.8  71.8
Abbreviation: N, sample size; HAMD, 17-item hamilton rating scale for depression; MADRS, montgomery-åsberg depression rating scale; CGI-I, clinical global impressions 
scale for improvement; CGI-S, clinical global impressions scale for severity; LTG, lamotrigine; OFC, olanzapine/fl uoxetine combination 
aNote that defi nitions of response vary with different studies: HAMD and MADRS defi nitions of response are 50% reduction from baseline scores for the respective 
scales; CGI-I defi nition of response is a rating of much improved or very much improved; CGI-S defi nition of response is a rating of 3 
bp < 0.05 vs placebo
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lamotrigine and placebo groups after Week 3. No signiﬁ cant 
treatment-emergent polarity switch was found.
In the second monotherapy study (Frye et al 2000) 
(Table 2), lamotrigine was compared with gabapentin and 
placebo in a double-blind, randomized, crossover trial on 31 
patients with refractory unipolar and bipolar affective illness 
requiring hospitalization. The diagnostic distribution of these 
patients was 6 unipolar illness, 11 bipolar I and 14 bipolar 
II disorder, the majority of the bipolar group (23 out of 25) 
had a rapid cycling course. Patients were randomized, with 
stratiﬁ cation by diagnostic classiﬁ cation, to receive sequen-
tial 6-week trials of each of the 3 treatment arms. Maximum 
tolerated doses of lamotrigine and gabapentin were used with 
mean daily doses being 274 mg and 3987 mg, respectively. 
Using the CGI for bipolar illness as primary outcome mea-
sure, 52% of the lamotrigine group had a rating of “much 
improved” or “very much improved”, compared with 26% of 
the gabapentin and 23% of the placebo groups (p = 0.031). 
When response rates were analysed by affective episode 
types, both mania (lamotrigine 44%, gabapentin 20%, pla-
cebo 32%) and depression (lamotrigine 45%, gabapentin 
26%, placebo 19%) showed similar non-signiﬁ cant trends. In 
an extension to this study with a bigger sample size (N = 45), 
of which there were 35 bipolar and 10 unipolar treatment-
refractory patients, response rates of 53% for lamotrigine, 
28% for gabapentin and 22% for placebo (p = 0.01), were 
reported (Obrocea et al 2002). Response to lamotrigine 
monotherapy was signiﬁ cantly correlated with a diagnosis 
of bipolar disorder, the male gender, exposure to fewer prior 
medication trials and a history of fewer prior hospitalizations 
for depression, although only the last two survived logistic 
regression. These studies lend further support for the efﬁ cacy 
of lamotrigine in bipolar depression, but their generalizability 
is restricted by their highly-refractory and diagnostically 
heterogeneous populations.
Brown and colleagues conducted a double-blind, random-
ized trial comparing the efﬁ cacy of olanzapine/ﬂ uoxetine 
combination (OFC) (N = 205) to lamotrigine (N = 205) 
as acute treatments in bipolar depression (Brown EB et al 
2006) (Table 1). They found that OFC showed signiﬁ cantly 
greater improvement than lamotrigine across the 7-week 
study period, as measured by CGI-S, MADRS and the Young 
Mania Rating Scale (YMRS), as well as a signiﬁ cantly shorter 
time to response. However, the prolonged dose titration of 
lamotrigine (over 5 weeks) relative to the study period could 
have inﬂ uenced the results. Lamotrigine, however, was 
associated with less adverse effects and showed comparable 
response and remission rates as OFC.
Adjunctive trials
Data also exists for the adjunctive use of lamotrigine in 
treatment-resistant bipolar depression. One such report 
stemmed from the Systematic Treatment Enhancement 
Program for Bipolar Disorder (STEP-BD) (Nierenberg et al 
2006). Patients (N = 66) in a major depressive episode who 
had not responded to combination mood stabilizer and anti-
depressant, were randomized, with equipoise stratiﬁ cation, 
to up to 16 weeks of open-label adjunctive treatment with 
lamotrigine, inositol or risperidone. No signiﬁ cant inter-group 
differences were found on primary outcome measure, which 
Table 2 Controlled trials of lamotrigine monotherapy in refractory bipolar disorder
Trial Study arms N Sample Trial length Response rate in percentagea
    in weeks
Frye  31 Refractory  6  CGI-I  CGI-I CGI-I 
et al 2000   disorder: 6  (sequential  overallb mania depression
 LTG  unipolar;  crossover  52 44 45
 Gabapentin  11 bipolar  design) 26 20 26
 Placebo  I; 14   23 32 19
   bipolar II    
Obrocea   45 Refractory  6   CGI-Ic
et al 2002 LTG  disorder:  (sequential   53
 Gabapentin  10  crossover   28
 Placebo  unipolar;  design)  22
   15 bipolar   
   I; 20   
   bipolar II   
Abbreviation: N, sample size; CGI-I, clinical global impressions scale for improvement; LTG, lamotrigine 
aCGI-I defi nition of response is a rating of much improved or very much improved
bp = 0.031
cp = 0.01
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was deﬁ ned using the DSM-IV criteria for full remission. 
However, remission rate was highest for lamotrigine (23.8% 
compared with 17.4% for inositol and 4.6% for risperidone), 
suggesting some superiority of adjunctive lamotrigine 
although the differences did not reach statistical signiﬁ cance. 
These results encourage further exploration of the adjunctive 
role of lamotrigine in treatment-resistant bipolar depression, 
but this trial on its own was hindered by low statistical power, 
equipoise randomization and open-label design.
Another trial studied the adjunctive use of lamotrigine 
in treatment-resistant depression, including a subset with 
bipolar II depression (N = 8) although the majority had uni-
polar depression (N = 15) (Barbosa et al 2003) (Table 3). 
The 23 patients were in a major depressive episode that had 
not responded to at least one antidepressant trial, which did 
not include ﬂ uoxetine. They were randomized to receive 
100 mg/day lamotrigine (N = 13) or placebo (N = 10), in 
addition to 20 mg/day of ﬂ uoxetine, for a period of 6 weeks. 
All other psychotropic medications were ceased. The groups 
did not signiﬁ cantly differ on HAMD, but the lamotrigine 
group was signiﬁ cantly superior to placebo in terms of 
improvement in CGI-S scores and response rate as measured 
by the CGI-I. There was no difference between the unipolar 
and bipolar II groups.
A few negative unpublished randomized, placebo-
controlled trials of lamotrigine in bipolar depression have 
been conducted (Data on ﬁ le 1999, 2002, 2006). A pooled 
meta-analysis of these trials has shown an efﬁ cacy signal for 
lamotrigine (Geddes, unpublished data). There are also small 
studies comparing lamotrigine to venlafaxine (McIntyre 
et al 2004) and to citalopram (Schaffer et al 2006) for bipolar 
depression, neither showing any advantage with lamotrigine.
Studies in rapid cycling
There is only a single reported double-blind, placebo-
controlled study of lamotrigine in rapid cycling bipolar 
disorder (Calabrese et al 2000) (Table 4). This trial recruited 
324 patients in various mood states (euthymia or active 
mood episode), but all meeting the DSM-IV criteria for rapid 
cycling bipolar disorder, into the preliminary stabilization 
phase. In this phase, lamotrigine was introduced and when 
the patient became affectively well, existing psychotropic 
agents were withdrawn. At the end of this phase, 182 patients 
emerged eligible to participate in the randomization phase, 
during which they were allocated to lamotrigine or placebo 
monotherapy for 6 months, using ﬂ exible lamotrigine dos-
ing from 100 to 500 mg per day. Time to additional phar-
macotherapy to treat emergent mood symptoms was the 
primary outcome measure, and this did not differ between the 
lamotrigine and placebo groups. Neither did the groups differ 
on secondary outcome measures such as changes in CGI-S 
and the global assessment scale (GAS). However, the two 
groups statistically diverged in their survival in study ﬁ gures 
in favor of lamotrigine, a difference that retained statistical 
signiﬁ cance in the bipolar II population when the subtypes 
were analyzed. 41% of the lamotrigine group completed 
the 6-month randomization phase without illness relapse, 
compared with 26% of the placebo group. This signiﬁ cant 
difference was again only observed for bipolar II disorder 
on subtype analysis.
A small (N = 14), open-label study also reported on 
the prophylactic efficacy of lamotrigine monotherapy in 
rapid cycling bipolar disorder (Walden et al 2000). This 
cohort of bipolar I disorder patients was treated with 
either lithium or lamotrigine monotherapy for one year, 
and found that 43% of the lithium group no longer met the 
criteria for rapid cycling (ie, more than four mood episodes 
in a year) compared with 86% of the lamotrigine group, 
with 43% of the latter having no episodes. Despite many 
methodological weaknesses, this study demonstrated 
positive findings in a literature-poor area, and observed 
that possibly greater benefits could be associated with 
Table 3 Randomized, controlled trials of adjunctive lamotrigine in bipolar disorder
Trial Study arms N Sample Trial length Response rate in percentagea
    in weeks
Barbosa    Treatment- 6 HAMD MADRS CGI-I 
et al 2003 LTG +  13 resistant major   76.9 76.9 84.6b
 fl uoxetine  depression: 15  
 Placebo +  10 unipolar; 8   50.0 40.0 30.0
 fl uoxetine  bipolar II
Abbreviation: N, sample size; CGI-I, clinical global impressions scale for improvement; LTG, lamotrigine 
aNote that defi nitions of response vary with different studies: HAMD and MADRS defi nitions of response are 50% reduction from baseline scores for the respective 
scales; CGI-I defi nition of response is a rating of much improved or very much improved.
bp = 0.013.
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the higher plasma lamotrigine levels (above 5 mg/L) that 
were recommended in epileptology.
Studies in maintenance treatment
In a continuation study to the afore-mentioned 7-week, 
double-blind, placebo-controlled trial of lamotrigine 
monotherapy in the treatment of bipolar I depression 
(Calabrese, Bowden, Sachs, et al 1999), 92% of those who 
had completed the controlled trial (N = 124) entered the 
1-year open-label lamotrigine continuation phase, although 
only 69 (56%) completed it with a mean duration of expo-
sure of 10.4 months (McElroy et al 2004). Those who had 
received placebo in the controlled trial showed signiﬁ cant 
reduction in MADRS scores as early as Week 4 (maximum 
mean decrease of 9.7 points), and all participants maintained 
their improved MADRS scores throughout the continuation 
phase. Furthermore, the proportion of patients reporting 
manic, hypomanic or mixed episodes during the one year 
of lamotrigine continuation was half that of the year before 
(31% versus 62%). Study design limitations including the 
allowance of concomitant psychotropic medications, nota-
bly with a third of the group receiving antidepressants and 
a minority on additional mood stabilizers, should be borne 
in mind. Nevertheless, this study provided support for the 
mood stabilizing in addition to antidepressant properties of 
lamotrigine.
Two 18-month placebo-controlled trials compared 
lamotrigine and lithium as maintenance monotherapy in 
bipolar I disorder, each focusing on a single pole of the illness 
at entry (Table 4). In one study (Calabrese et al 2003), patients 
currently or recently in a major depressive episode were ﬁ rst 
stabilized on lamotrigine in an 8- to 16-week open-label phase, 
before being randomized to receive lamotrigine (N = 221), 
lithium (N = 121) or placebo (N = 121) monotherapy for up 
to 18 months. Using time from randomization to interven-
tion for any emergent mood episode as outcome measure, 
lamotrigine and lithium did not differ from one another, but 
both were superior to placebo. Depressive episodes outnum-
bered mania by a ratio of 3:1 as cause for intervention. When 
time to intervention was examined according to the polarity 
of the emergent mood episode, lamotrigine but not lithium 
was superior to placebo for depression, whereas the reverse 
held true for manic, hypomanic and mixed episodes. Of inter-
est, out of the three daily lamotrigine doses studied (50 mg, 
200 mg and 400 mg), only patients on 200 mg showed sig-
niﬁ cant advantage over placebo in time to intervention for 
both overall mood episodes and depressive episodes. The 
second study (Bowden et al 2003) used a similar design on 
a smaller sample (N = 175) of bipolar I disorder patients 
with recent manic or hypomanic episodes, and produced 
matching results, which were the superiority of lamotrigine 
and lithium to placebo on survival time to intervention, and 
the differential superiority of lamotrigine and lithium with 
regards to depression and mood elevation, respectively.
When data from both studies were pooled, lamotrig-
ine again emerged superior to placebo and lithium in the 
Table 4 Randomized, controlled trials of lamotrigine monotherapy in prophylaxis of bipolar disorder
Trial Study arms N Sample Trial length  Effi cacya 
    in months
Calabrese    Stabilized,  6 No  Survival time
et al 2000   rapid-cycling   intervention 
 LTG 93 bipolar I or II  50 18 weeks
 Placebo 89 patients  44 12 weeks
Calabrese    Stabilized  18 No  Survival time
et al 2003   bipolar I  intervention 
 LTG 221 patients with  18 200 daysa
 Lithium  121 index   17 170 daysa
 Placebo 121 depressive   10 93 days
   episode   
Bowden    Stabilized  18 No  Survival time
et al 2003   bipolar I  intervention 
 LTG 59 patients with  53 141 daysb
 Lithium 46 index mania  61 292 daysb
 Placebo 70 or hypomania  30 85 days
Abbreviation: N, sample size; LTG, lamotrigine
aEffi cacy outcome defi nitions: No intervention refers to the proportion (in percentage) of patients who did not required treatment for an emergent mood episode; Survival 
time refers to the median time until treatment was required for an emergent mood episode 
ap = 0.029 for LTG vs placebo, p = 0.029 for lithium vs placebo, with no signifi cant difference between LTG and lithium
bp = 0.02 for LTG vs placebo, p = 0.003 for lithium vs placebo
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prolongation of time to intervention for depression. Both 
lamotrigine and lithium were superior to placebo at prolong-
ing the time to intervention for manic, hypomanic and mixed 
episodes, but only lithium remained superior after adjusting 
for index mood type. It was also apparent that the index epi-
sode was strongly predictive of the polarity of the subsequent 
episode, which could potentially inform treatment decisions 
in bipolar maintenance (Goodwin et al 2004).
Studies in comorbid disorders
Lamotrigine has been suggested as effective in the treatment 
of comorbid bipolar and borderline personality disorder 
(Preston et al 2004), comorbid bipolar disorder and alcohol 
dependence (Rubio et al 2006), and comorbid bipolar disor-
der and cocaine dependence (Brown et al 2003; Brown E et al 
2006). However, these studies all have limited methodologi-
cal rigor that impact on the validity of their ﬁ ndings.
Safety and tolerability 
of lamotrigine
Placebo-controlled trials of lamotrigine in bipolar disorder, 
including the 18-month studies, suggest it to be well-tolerated 
with a comparable adverse event proﬁ le to placebo, without 
appearing to have signiﬁ cant impact on laboratory param-
eters, body weight and sexual functioning or to have mood 
destabilizing effects (Bowden et al 2004). The most common 
treatment-emergent adverse event is headache, which was 
found to occur statistically more frequently than placebo in 
one study (Calabrese, Bowden, Sachs et al 1999).
The most worrying adverse effect of lamotrigine is the 
rare but potentially lethal Stevens-Johnson syndrome (SJS) 
or toxic epidermal necrosis (TEN). These syndromes are 
understood to be fundamentally the same drug-induced cu-
taneous reaction characterized by blistering and epidermal 
detachment resulting from keratinocytic apoptosis, but denote 
differing severity with SJS deﬁ ned as <10% body surface 
area epidermal detachment, SJS/TEN 10% to 30% detach-
ment and TEN >30% detachment. Mortality increases from 
1%–5% for SJS to 25%–35% for TEN. Despite the promis-
ing therapeutic outcome of intravenous immunoglobulins, 
prevention and early diagnosis with discontinuation of the 
causative drug remain the best strategy (Chosidow et al 2005; 
French et al 2006). The occurrence of rash is common in both 
lamotrigine- and placebo-exposed groups in bipolar trials, 
but the incidence of serious rash, deﬁ ned as that requiring 
hospitalization and lamotrigine discontinuation or reported 
as SJS or TEN, is low at approximately 0.1% (Bowden 
et al 2004). These have typically occurred in the ﬁ rst 8 weeks 
of drug initiation (Messenheimer et al 1998). A three-fold, 
albeit still low, incidence was found in earlier lamotrigine 
trials for epilepsy, a difference that was attributed to higher 
initial doses, rapid dose escalation and concurrent valproate 
use (Messenheimer 1998). The use of additional precautions 
aimed at reducing antigen exposure, above the standard 
product information precautions, has not been found to lower 
the risk of non-serious rash in a randomized trial (N = 1175), 
and no serious rash was reported to allow comparison (Ketter 
et al 2006). There have been case reports of successful slow-
titration rechallenge with lamotrigine after the occurrence of 
serious rash (Tavernor et al 1995; Besag et al 2000; Manfredi 
et al 2004).
There are reports of tics (Sotero de Menezes et al 2000; 
Seemuller et al 2006), mania (Raskin et al 2006), hallucina-
tions (Uher and Jones 2006) and hyponatraemia (Mewasingh 
et al 2000) being associated with lamotrigine.
Available data on the teratogenicity of lamotrigine comes 
from epileptic patients. From the United Kingdom epilepsy 
and pregnancy register, which prospectively collects data on 
women with epilepsy who become pregnant, lamotrigine has 
been associated with a rate of major congenital malforma-
tions of 3.2%, compared with 3.5% for epileptic women not 
on anticonvulsants during pregnancy and 4.2% for those 
on anticonvulsants. Speciﬁ cally, there was a trend towards 
fewer major malformations for pregnancies exposed only 
to lamotrigine than to valproate, and a signiﬁ cant dose-
dependent relationship was found for lamotrigine, with 
major malformation rates of 1.3% for daily doses under 100 
mg, 1.9% for 100–200 mg and 5.4% for doses exceedingly 
200 mg. This latter ﬁ gure was comparable with that for val-
proate daily doses of 1000 mg or less (5.1%) and lower than 
that for valproate daily doses over 1000 mg (9.1%) (Morrow 
et al 2006). Data from the international lamotrigine preg-
nancy Register provided a major malformation rate of 2.9% in 
ﬁ rst trimester monotherapy exposure (N = 414) (Cunnington 
and Tennis 2005).
The potential neonatal adverse effects of breastfeeding 
while on lamotrigine are unclear. Studies indicate a relatively 
high level of drug transmission in the breast-milk, with neo-
natal plasma lamotrigine levels gauged to be approximately 
25%–30% that of the mother’s (Tomson et al 1997; Ohman 
et al 2000; Liporace et al 2004), although the clinical implica-
tions of such levels on the infant remain speculative.
Patient-focused perspectives
Quality of life is an important consideration for any treat-
ment decision, and encompasses the aspects of treatment 
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efﬁ cacy, safety and tolerability, including the evaluation 
of seemingly trivial drug effects that may cause enduring 
functional impairment. Lamotrigine’s tolerability, especially 
in comparison with lithium and other mood stabilizers, is a 
factor conducive to adherence, which is a confronting issue 
in bipolar disorder with an estimated 51% of patients unable 
to adhere to prescribed medications in a 1-year follow-up 
study (Keck et al 1997).
Lamotrigine appears to hold two speciﬁ c advantages 
among the bipolar pharmacotherapies in tolerability terms, 
namely its apparent lack of adverse effects on weight (Sachs 
et al 2006) and cognitive functions. These are desirable prop-
erties considering the higher prevalence of obesity (Simon 
et al 2006) and metabolic syndrome (Fagiolini et al 2005) 
in bipolar patients, and the evidence for marked cognitive 
dysfunction in this population (Robinson et al 2006). There 
is preliminary support for improved cognitive functioning 
on lamotrigine monotherapy or adjunctive therapy in bipolar 
patients (Khan et al 2004), and for its superior neurocognitive 
proﬁ le over other anticonvulsants, such as carbamazepine, 
valproate (Daban et al 2006) and topiramate (Blum et al 
2006; Smith et al 2006). There are also suggestions that 
lamotrigine may exert a neuroprotective effect (Wiard et al 
1995; Trojnar et al 2002), although conﬁ rmatory evidence 
is wanting. In a double-blind, randomized crossover study 
comparing patient preference of lamotrigine and topira-
mate using healthy subjects, the majority (70%) preferred 
lamotrigine (Werz et al 2006), which lends support for its 
acceptability to patients.
Conclusion
Despite a broad spectrum of effect and large magnitudes of 
improvement in uncontrolled studies, the available random-
ized controlled trials of lamotrigine in the treatment of bipolar 
disorder have only demonstrated convincing efﬁ cacy in the 
prophylaxis of bipolar depression. There is weaker support 
for its efﬁ cacy in acute bipolar I depression, refractory uni-
polar and bipolar depression, and rapid cycling illness. The 
timeframe of response seems to be several weeks, perhaps 
as early as three, and a daily lamotrigine dose of 200 mg 
appears to be effective for its bipolar indications with low-
ered risks of teratogenicity and serious rash. The utilization 
of slow titration methods has proven a useful mechanism 
for avoiding serious side effects but may impede the acute 
efﬁ cacy of the drug.
It must be borne in mind, however, that the total number of 
clinical trials in this area is small. There are four randomized 
controlled trials in mania producing inconclusive results due to 
marred methodologies, several published randomized trials in 
bipolar depression of varying designs, lamotrigine utilization 
and sample characteristics, and only one randomized con-
trolled trial in rapid cycling illness. This limited evidence base 
stands favorably in the area of bipolar depression treatment, 
which is marked by a paucity of safe and efﬁ cacious treat-
ment options. As the evidence stands at present, lamotrigine 
seems to be a generally well-tolerated and, providing that dose 
titration and concurrent valproate precautions are followed, a 
safe treatment option whose main disadvantage is a restricted 
efﬁ cacy repertoire in mania, compared with the best-available 
standard of lithium. Its advantages are primarily a favorable 
adverse effect proﬁ le and evidence of its superior efﬁ cacy in 
the prophylaxis of bipolar depression, which should be its 
main ﬁ rst-line indication. Consideration of bipolar subtype 
and index polarity in acute episodes may be helpful, as it 
may provide evidence-based guidance on the selection of the 
maintenance agent. More speciﬁ cally, bipolar disorder pre-
senting in manic phase would suggest lithium as the preferred 
maintenance, whereas bipolar II disorder or an index bipolar 
depressive episode may indicate lamotrigine as a suitable 
option, in monotherapy or combination treatment, especially if 
lithium is relatively contraindicated. Predictors of lamotrigine 
response include atypical depression, comorbid anxiety and 
substance use, failure to respond to lithium, valproate or car-
bamazepine, and a family history of substance use or anxiety 
(Narasimhan and Buckley 2006).
Practice guidelines vary in their recommendations, but 
lamotrigine is generally placed as ﬁ rst-line treatment for both 
acute bipolar depression and bipolar maintenance (Ameri-
can Psychiatric Association 2002; Grunze et al 2002; The 
Royal Australian and New Zealand College of Psychiatrists 
2004; Calabrese et al 2004; Grunze et al 2004; Suppes et al 
2005; Yatham et al 2005). The Canadian network for mood 
and anxiety treatments (CANMAT) guidelines are perhaps 
the most encompassing in their bipolar indications for 
lamotrigine, as they additionally include ﬁ rst-line treatment 
for rapid cycling bipolar disorder, ﬁ rst-line maintenance for 
bipolar II disorder, and second-line treatment for bipolar II 
depression (with no ﬁ rst-line treatment options) (Yatham 
et al 2005). These recommendatory variations seem to arise 
from different expectations of evidence base standards, and 
given the limited quantity and quality of clinical trials, the 
incorporation of lamotrigine for ﬁ rst-line indications beyond 
bipolar depression maintenance would seem to reﬂ ect clinical 
need and the paucity of alternatives.
However, the role deﬁ nition of lamotrigine in the treat-
ment of bipolar disorder may yet expand. In particular, 
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its usefulness in refractory affective disorders and bipolar 
subsets, including the soft bipolar spectrum, is encouraging 
and may become better understood. Timeframes for optimal 
response may differ in certain subsets of affective disorders, 
which may possibly explain the lengthy mean time to onset 
of response reported by one study (Ginsberg 2006). This 
suggests that an adequate trial of lamotrigine may need to 
be correspondingly lengthy in order not to miss this delayed 
onset of action.
Disorders of the bipolar spectrum are aetiologically and 
phenotypically heterogeneous and complex, and the likeli-
hood of monotherapy succeeding in the treatment and main-
tenance of all illness phases is low. A mood stabilizer, when 
most stringently deﬁ ned, is an agent that is efﬁ cacious in the 
treatment of both acute mania and bipolar depression, and 
in the prophylaxis of both poles of the illness. Only lithium 
can fully satisfy this criteria (Bauer and Mitchner 2004), and 
yet it is not unsurpassable in its efﬁ cacy in individual aspects 
of bipolar management, as exempliﬁ ed by lamotrigine’s 
comparative superiority in depression prophylaxis. There-
fore, rather than seeking for the ultimate single agent mood 
stabilizer, targeting therapy to individual clinical needs and 
the use of mood stabilizing cocktails may be more strategic 
approaches to tailor for the illness characteristics of patients 
with bipolar disorder, and better reﬂ ect the modern concep-
tualization of bipolarity and clinical practice. The role of 
lamotrigine in this future is yet to be fully deﬁ ned.
Practical summary points
• Lamotrigine has demonstrated its efﬁ cacy most convinc-
ingly in the prophylaxis of bipolar depression.
• Weaker efﬁ cacy data are available in the treatment of 
acute bipolar I depression, refractory unipolar and bipolar 
depression, and rapid cycling illness.
• The timeframe to response with lamotrigine is lengthy, 
and seems to lie in the range of several weeks.
• The therapeutic daily dose range appears to lie between 
200 to 400 mg, with the majority of studies demonstrating 
efﬁ cacy at the lower end of this range.
• A standard initiation and titration practice involves the 
initiation of lamotrigine at a daily dose of 25 mg, and 
increasing this to 50 mg per day after one to two weeks, 
then doubling the dose every one to two weeks until a 
dose of 200 mg per day is reached. 
• A more cautious initiation and dose titration schedule 
should be undertaken if either valproate or sertraline is 
concurrently administered, due to potential drug interac-
tions that may increase the risk of toxicity and skin rash.
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